// App-Quantinova.ai

: Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.

Researchers

Presenter

  • Mark R. Middleton

Principal Investigators

  • Ioannis Karydis

  • Xin Lu

  • Aileen Ryan

  • Ralph Rudolph Venhaus

  • Kristen Auferio Ramirez

  • Mary Macri

  • Toni Ricciardi

  • Megan Lawrence

  • Martin Scott-Brown

  • Gareth Owen Griffiths

  • Linda Collins

  • Lucinda Griffiths

  • Sam Wilding

  • Simon Lord

  • Richard Owen

  • Russell D. Petty

Medical Centers

  • Churchill Hospital, Oxford, United Kingdom

  • Ludwig Cancer Research, New York, NY

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • University of Southampton Hospital Trust, Southampton, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • University of Dundee, Dundee, United Kingdom

  • University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine and oxaliplatin

  • Fluorouracil

  • Adrucil injection

  • Capecitabine

  • Oxaliplatin

  • Durvalumab

  • leucovorin

  • Adk3 + Docetaxel

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02735239

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved